AOD-9604 vs Cagrilintide
Metabolic
AOD-9604
C-terminal fragment of human growth hormone studied for lipolytic activity without the growth-promoting effects of the full hormone.
Metabolic
Cagrilintide
Long-acting amylin analog studied at calcitonin and amylin receptors — a satiety pathway mechanistically distinct from incretin agonism.
Side by side
| Dimension | AOD-9604 | Cagrilintide |
|---|---|---|
| Molecular weight A 2.4× difference in mass — these are not comparable on a milligram-for-milligram basis. | 1815.08 g/mol | 4409 g/mol |
| Size class | mid-length peptide | long peptide |
| CAS number | 221231-10-3 | 1415456-99-3 |
| Research area | metabolic | metabolic |
| Sequence | Not published as a linear sequence | Not published as a linear sequence |
| Available sizes | 5mg | 10mg |
| Entry price | $44 | $99 |
| Cost per mg | $8.80 | $9.90 |
Mechanism
AOD-9604
AOD-9604 corresponds to residues 176-191 of human growth hormone, the C-terminal region associated in early work with the hormone's effects on adipose tissue. The research premise is separation of function: retaining lipolytic activity while excluding the IGF-1-mediated growth signaling of full-length hGH. Published human trial results have been considerably more modest than the preclinical rodent data suggested — a gap worth knowing before designing around it.
Cagrilintide
Cagrilintide is an acylated analog of human amylin, the peptide co-secreted with insulin from pancreatic β-cells. It acts at the calcitonin receptor and amylin receptor subtypes, a pathway entirely separate from GLP-1 and GIP signaling. Research interest centers on whether amylin and incretin pathways are additive, which is why it appears frequently in combination studies alongside semaglutide.
Research applications
AOD-9604
- Lipolysis and β-adrenergic pathway assays in adipocyte culture
- Comparative studies against full-length hGH
- IGF-1 independence verification studies
Cagrilintide
- Amylin and calcitonin receptor binding studies
- Combination pharmacology with incretin agonists
- Satiety signaling research in preclinical models
- Gastric emptying rate assays
Common questions
What is the difference between AOD-9604 and Cagrilintide?
AOD-9604 is c-terminal fragment of human growth hormone studied for lipolytic activity without the growth-promoting effects of the full hormone. Cagrilintide is long-acting amylin analog studied at calcitonin and amylin receptors — a satiety pathway mechanistically distinct from incretin agonism. They differ in molecular weight (1815.08 vs 4409 g/mol) and in the pathways they are studied against.
Which is more cost-effective per milligram, AOD-9604 or Cagrilintide?
AOD-9604 is lower at approximately $8.80 per milligram at its best tier, against $9.90 for the other. Cost per milligram is only meaningful relative to the concentrations a given protocol requires, since these compounds are not used at comparable masses.
Can AOD-9604 and Cagrilintide be studied together?
Combination designs appear in the published literature for a number of these compounds. Whether it is appropriate for a given protocol depends entirely on the model and endpoint. We supply research compounds and do not provide protocol guidance — consult the primary literature for your specific model.
How should AOD-9604 and Cagrilintide be stored?
Store lyophilized at -20°C protected from light. Reconstituted at 2-8°C for up to 30 days. For Cagrilintide: Store lyophilized at -20°C protected from light. Reconstituted at 2-8°C for up to 30 days.
All products are intended strictly for laboratory research use. Not for human or veterinary use. Not for diagnostic or therapeutic use. Not a drug, food, or cosmetic.
Comparison generated from NuVida Vital catalog data. Every specification is reconciled against the certificate of analysis for the shipped batch.